|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT01246284 |
|
Date of registration:
|
08/11/2010 |
|
Primary sponsor: |
|
|
Public title:
|
The Efficacy and Safety of Different Concentrations of Localized Injections of Steroids in the Treatment of Alopecia Areata
|
|
Scientific title:
|
Efficacy and Safety of Different Concentrations of Intralesional Triamcinolone Acetonide in Alopecia Areata: A Prospective, Randomized, Double-blind, Placebo-controlled Study |
|
Date of first enrolment:
|
December 2010 |
|
Target sample size:
|
100 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT01246284 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Canada
| | | | | | | |
|
Contacts
|
|
Name:
|
Mohammed AlJasser |
|
Address:
|
|
|
Telephone:
|
778-859-5522 |
|
Email:
|
mj_derma@hotmail.com |
|
Affiliation:
|
|
|
|
Name:
|
Jerry Shapiro, MD FRCPC |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University of British Columbia |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Age > 18 years
- Less than 50% scalp involvement
- Patients should have a patch of at least 4.5 cm in the smallest diameter
Exclusion Criteria:
- Current episode of alopecia areata for longer than 2 years
- Evidence of hair regrowth at baseline
- Patients who received treatment with a topical, intralesional, or systemic agent
within the past month
- Rapidly progressing disease
- Hypersensitivity to Triamcinolone acetonide or vehicle
- Pregnancy or breast-feeding
Age minimum:
19 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Alopecia Areata
|
|
Intervention(s)
|
|
Drug: Triamcinolone acetonide
|
|
Other: Normal saline
|
|
Primary Outcome(s)
|
|
Hair growth
[Time Frame: 4-6 weeks after each treatment session]
|
|
Secondary Outcome(s)
|
|
Side effects
[Time Frame: 4-6 weeks after each treatment session]
|
|
Secondary ID(s)
|
|
H10-02231
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|